Cite
HARVARD Citation
Eyre, T. et al. (2019). A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL. Hematological oncology. 37 (4), pp. 352-359. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Eyre, T. et al. (2019). A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL. Hematological oncology. 37 (4), pp. 352-359. [Online].